Asked by: Baroness Afshar (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty's Government what assurance, if any, they have received that medication brought from new sources other than the EU will meet the same standards as present.
Answered by Baroness Blackwood of North Oxford
All human medicines marketed in the United Kingdom must meet stringent requirements for quality, safety and efficacy set out in UK medicines legislation and supporting guidelines. These apply regardless of the source of the medicine.
The Medicines and Healthcare products Regulatory Agency (MHRA), the Government body responsible for the safety and licensing of medicines in the UK, regularly inspect pharmaceutical manufacturing plants in the UK and in third countries.
Regardless of the location of the site of manufacture, the manufacturer must demonstrate to the MHRA that the product is manufactured according to the registered UK licence (marketing authorisation) and to at least the minimum standard detailed in the European Union Guide to Good Manufacturing Practice.
In addition, each batch of medicine manufactured in a third country is tested within the UK on import and the manufacturing document reviewed by the license holders Qualified Person before being certified for release to the market.
All these measures will remain in place if the UK leaves the EU.
Asked by: Baroness Afshar (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty's Government what plans they have to implement the Prevent Strategy within the NHS as a safeguarding measure to protect those with care and support needs.
Answered by Lord O'Shaughnessy
The Department is committed to ensuring that the National Health Service fully embeds the Prevent Statutory Duty of 2015 within its safeguarding responsibilities.
Great strides have been taken to embed Prevent within the health sector to date. For example, since the Prevent Duty made training mandatory over 830,000 NHS staff have received Basic Prevent Awareness training and over 470,000 have attended advanced training.
The Department is committed to engaging with relevant professional bodies and ensure that further opportunities to develop bespoke training for health professionals are undertaken.